Use of the Dopamine Transporter Striatal Binding Ratio as a Biomarker in Trials Regarding Early- to Mid-Stage Parkinson's Disease Modification
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials
Mov Disord Clin Pract 2024 Aug 22;[EPub Ahead of Print], N Vijiaratnam, C Girges, D Athauda, A King, G Auld, R McComish, K Chowdhury, S Skene, K Maclagan, KR Chaudhuri, V Libri, J Dickson, T FoltynieFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.